By Budi Oetomo Narendra 
Ebola virus disease (EVD) and hantavirus infections have recently resurfaced as subjects of intense focus within the international public health community, underscoring the enduring and serious risks they present. While fundamentally distinct in their virology, epidemiology, and geographical prevalence, both pathogens command rigorous infection prevention and control (IPAC) measures due to their potential for severe illness and, in some cases, significant mortality rates. The renewed attention has been partly spurred by recent articles published in the CMAJ (Canadian Medical Association Journal), which have disseminated crucial, updated information for healthcare professionals tasked with identifying, managing, and containing these complex diseases. These publications serve as a timely reminder of the critical importance of preparedness, surveillance, and robust clinical protocols in mitigating the threat posed by emerging and re-emerging viral diseases.
Hantavirus: A Silent Threat from the Wild
Hantavirus, a zoonotic pathogen primarily transmitted to humans through contact with infected rodents or their excretions, remains a nationally reportable disease in Canada, reflecting its persistent, albeit low-level, public health threat. Annually, public health authorities in Canada typically confirm and report approximately four to five cases. The vast majority of these infections are acquired in agricultural regions, particularly across the Western provinces of Manitoba, Saskatchewan, Alberta, and British Columbia, where human populations often interface with rodent habitats. The environmental factors, including agricultural practices and rodent population dynamics, play a significant role in determining the risk of human exposure.
Global Distribution and Clinical Manifestations
Hantaviruses are a diverse group of RNA viruses, with their specific strains dictating both their geographical distribution and the clinical syndrome they cause. In North and South America, infections are predominantly associated with Hantavirus Cardiopulmonary Syndrome (HCPS), a severe and often fatal respiratory illness. The Andes virus, a particular strain endemic to South America, has garnered specific concern due to its unique capacity for person-to-person transmission, a rare characteristic among hantaviruses. This capability significantly elevates its pandemic potential and the stringency of required IPAC measures compared to other hantavirus strains.
In contrast, hantaviruses prevalent in Europe and Asia are more commonly linked to Hemorrhagic Fever with Renal Syndrome (HFRS). While also serious, HFRS typically presents with different clinical features, primarily affecting the kidneys and vascular system rather than the lungs, as seen in HCPS. Both forms of hantavirus infection generally share a similar incubation period, ranging from two to four weeks post-exposure. Initial symptoms are often non-specific and flu-like, including fever, headache, myalgia (muscle aches), and abdominal pain, making early differential diagnosis challenging without a high index of suspicion and detailed exposure history.
Diagnosis, Treatment, and Infection Control for Hantavirus
Accurate and timely diagnosis of hantavirus infection is critical for patient management and public health response. Diagnosis relies on specific laboratory tests, primarily serology (detecting antibodies to the virus) and polymerase chain reaction (PCR) testing, which identifies viral genetic material. In Canada, these specialized diagnostic services are performed by the National Microbiology Laboratory in Winnipeg, serving as a central reference point for confirmatory testing.
Currently, there are no approved antiviral medications or specific vaccines available for hantavirus infections. Treatment is therefore entirely supportive, focusing on managing symptoms, maintaining organ function, and addressing complications as they arise. For HCPS, this often involves aggressive respiratory support, including mechanical ventilation, and careful fluid management to prevent pulmonary edema. The lack of targeted therapeutics underscores the critical importance of prevention and early supportive care.
Given the potential for human-to-human transmission associated with the Andes virus, suspected cases necessitate stringent infection prevention and control measures. Patients suspected of having an Andes virus infection must be immediately isolated using airborne, droplet, and contact precautions. This multifaceted approach aims to prevent transmission through respiratory aerosols, larger droplets, and direct or indirect contact with contaminated surfaces or bodily fluids. Infectious disease specialists play a crucial role in guiding patient management, while prompt notification of public health authorities is mandatory to initiate contact tracing, assess potential exposures, and implement community-level control measures.
Ebola Virus Disease: A Persistent Threat in Conflict Zones
Ebola virus disease (EVD), caused by one of several species of the Ebolavirus genus, has periodically erupted in devastating outbreaks across Central and West Africa since its initial identification in 1976. Researchers widely believe that fruit bats serve as the natural reservoir for the virus, with spillover events to humans occurring through contact with infected bats or intermediate hosts, such as non-human primates or forest antelope. Once in the human population, the virus spreads rapidly through direct contact with the bodily fluids of infected individuals—including blood, vomit, diarrhea, and semen—as well as through contact with objects or surfaces contaminated with these fluids. Traditional burial practices involving close contact with the deceased have also been identified as significant drivers of transmission during outbreaks.
A History of Outbreaks and Evolving Challenges
The history of EVD is marked by episodic outbreaks, often localized but occasionally escalating into major epidemics. The 2014-2016 West African Ebola epidemic, caused by Zaire ebolavirus, stands as the largest and most complex outbreak since the virus was discovered, resulting in over 11,000 deaths across Guinea, Liberia, and Sierra Leone. This catastrophic event highlighted critical gaps in global health security, surveillance, and rapid response mechanisms. It also spurred unprecedented international collaboration in research and development, leading to significant advancements in diagnostics, vaccines, and therapeutics.
More recently, the Democratic Republic of Congo (DRC) has faced numerous outbreaks, including a prolonged and challenging epidemic in its eastern provinces from 2018-2020. The current outbreak under scrutiny in the DRC involves the Bundibugyo ebolavirus strain, which carries a reported fatality rate of 30% to 50%. This particular strain adds a layer of complexity as it differs from the Zaire ebolavirus strain, for which effective vaccines and treatments have been developed. Operating in regions often characterized by civil unrest, population displacement, and limited healthcare infrastructure, EVD response efforts in the DRC face compounded challenges, hindering rapid containment and effective public health interventions.
Ebola Symptoms, Diagnosis, and Screening
While Ebola is often sensationally associated with visible bleeding, hemorrhagic symptoms actually develop in fewer than half of all patients. The typical initial presentation is often non-specific, characterized by a sudden onset of fever (38°C or higher), intense fatigue, muscle pain, and gastrointestinal problems such as diarrhea, vomiting, and abdominal pain. The incubation period for EVD can range from a short two days to as long as 21 days, making contact tracing and monitoring of exposed individuals a lengthy and resource-intensive undertaking.
Diagnosis is confirmed through PCR testing, which detects viral genetic material in blood or other bodily fluids. Given the non-specific nature of early symptoms, clinical suspicion is paramount. Individuals who develop symptoms and have possible exposure risks must be promptly evaluated and tested. This includes travelers recently returned from countries experiencing EVD outbreaks, as well as individuals who have had close contact with confirmed EVD patients, or with potentially infected bats, primates, or game animals from affected regions. Robust screening protocols at points of entry and within healthcare settings are crucial for early detection and isolation.
Advances and Limitations in Ebola Treatment and Prevention
The experience of recent large-scale outbreaks has dramatically advanced the field of EVD prevention and treatment. For Zaire ebolavirus, significant progress has been made: highly effective vaccines, such as rVSV-ZEBOV, have been developed and deployed, proving instrumental in controlling outbreaks. Furthermore, two antiviral treatments (monoclonal antibody therapies) have demonstrated substantial efficacy, reducing mortality rates from approximately 50% to as low as 35% in clinical trials. These breakthroughs represent a paradigm shift in the fight against EVD, offering genuine hope where previously only supportive care was available.
However, these advances are strain-specific. A critical limitation in the current public health response is the absence of approved vaccines or specific antiviral medications for Bundibugyo ebolavirus. For patients infected with this particular strain, supportive care remains the cornerstone of treatment. This includes aggressive fluid and electrolyte management, maintenance of oxygen status and blood pressure, treatment of complicating infections, and pain management. The lack of specific therapeutics for all EVD strains underscores the ongoing need for broad-spectrum antiviral research and the development of pan-Ebola countermeasures.
In all suspected Ebola cases, regardless of the strain, rigorous infection prevention and control procedures are non-negotiable. Health Canada, mirroring international guidelines from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), recommends detailed screening and assessment protocols. Healthcare workers caring for suspected or confirmed EVD patients must utilize extensive personal protective equipment (PPE), including a fit-tested N95 respirator, face shield, gloves (often double gloved), and fluid-impermeable clothing (gowns or coveralls). Strict protocols for donning and doffing PPE are equally vital to prevent self-contamination.
The Imperative of Infection Prevention and Control (IPAC)
The renewed focus on both hantavirus and Ebola, despite their differences, highlights a shared critical need: robust infection prevention and control. For hantavirus, particularly the Andes strain, and universally for Ebola, IPAC measures are the primary line of defense against transmission within healthcare settings and the wider community. These measures encompass patient isolation, stringent hand hygiene, appropriate use of PPE, safe management of patient care equipment, and proper waste disposal. The capacity of healthcare systems to implement and sustain these measures is a direct determinant of outbreak containment success.
Healthcare professionals are at the forefront of this defense. Their training, adherence to protocols, and vigilance are paramount. This includes not only frontline clinicians but also laboratory personnel, environmental services staff, and public health officials involved in surveillance and contact tracing. The multidisciplinary nature of IPAC underscores the need for comprehensive training and regular drills to ensure readiness for potential exposure scenarios.
Global Health Implications and Preparedness
The ongoing challenges posed by Ebola and hantavirus serve as stark reminders of the interconnectedness of global health and the constant threat of emerging and re-emerging infectious diseases. The relatively low incidence of hantavirus in Canada belies its potential for severe outcomes, while Ebola outbreaks in Africa underscore the fragility of health systems in resource-limited settings and the risk of international spread through modern travel.
International health organizations, such as the WHO, the CDC, and national bodies like the Public Health Agency of Canada (PHAC), play pivotal roles in global surveillance, risk assessment, and coordinated response efforts. They issue travel advisories, develop clinical guidelines, and support capacity building in affected regions. The investment in these organizations and in national public health infrastructure is not merely a humanitarian gesture but a critical component of global security.
Further research and development are crucial. While significant strides have been made against Zaire ebolavirus, the lack of specific countermeasures for Bundibugyo ebolavirus and all hantavirus strains represents a persistent vulnerability. Sustained funding for vaccine and therapeutic research, particularly for neglected tropical diseases and those impacting vulnerable populations, is essential. Moreover, strengthening laboratory capacities globally, enhancing epidemiological surveillance, and fostering rapid information sharing are vital to detect outbreaks early and mount effective responses.
The economic and social implications of outbreaks extend far beyond immediate health costs. They can disrupt trade, tourism, and education, destabilize economies, and exacerbate social inequalities. For instance, the West African Ebola epidemic had a devastating impact on the economies of Guinea, Liberia, and Sierra Leone, setting back development gains by years. Similarly, even localized hantavirus outbreaks can cause significant anxiety and necessitate public health interventions that carry economic costs.
As stated by leading public health experts, "Vigilance is our greatest tool against these evolving threats. While medical science continues to advance, our foundational defenses—strong surveillance, robust IPAC, and informed public health action—remain indispensable." The renewed attention to Ebola and hantavirus reinforces the ongoing need for global collaboration, sustained investment in public health, and unwavering commitment to scientific research to protect populations worldwide from these persistent viral adversaries.
